

APP

Research Grade Solanezumab

Catalog No.	DHC12505A DHC12505B	Quantity:	100 µg 1.0 mg
Alternate Names:	LY2062430, CAS: 955085-14-0		
Description:	Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the Aβ peptide. It recognizes soluble monomeric, not fibrillar, Aβ. Solanezumab (formerly known as LY2062430) is a monoclonal antibody being developed by Lilly as a potential therapy for people with mild cognitive impairment caused by Alzheimer's disease.		
UniProt ID (target):	P05067		
Target:	Human Amyloid-beta precursor protein		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO		
Isotype:	Human IgG1 kappa		
Formulation:	0.01M PBS buffer, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
INN:	Solanezumab		
Applications:	Functional studies		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.